Experimental and computational methods reveal enhanced antibacterial properties in a cocrystal of metronidazole and p-hydroxybenzoic acid, implying implications for drug design.
In this work, a new cocrystal composed of metronidazole (MTZ) and P-hydroxybenzoic acid (PHBA) was synthesized using the slow evaporation method. Characterization by PXRD, DSC, FTIR, and SEM confirmed the formation of a new crystalline phase distinct from the starting materials. Computational analysis based on QTAIM revealed two possible forms stabilized by different hydrogen-bonding patterns: in form I, two hydrogen bonds link the carboxyl group of PHBA to the hydroxyl group of MTZ, whereas in form II, a single hydrogen bond forms between the hydroxyl groups of MTZ and PHBA. This suggests potential polymorphism, further supported by recrystallization experiments and PXRD diffractograms indicating a phase transformation. Molecular docking studies showed that cocrystallization enhanced the antibacterial activity of Metronidazole against Clostridium difficile , and that the two polymorphs exhibited distinct binding affinities, suggesting that polymorphism can influence the biological performance of the cocrystal.
No takes yet. Share an insight, caveat, or question.
Chaib et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: